How did Eli Lilly's other fees fluctuate in 2024?

Eli Lilly's other fees appear to have been relatively stable or showed slight improvements in 2024, considering the available data.

1. No Record of Other Fees: According to the information available, there were no recorded other fees for Eli Lilly in 2024.

2. Focus on Revenue Growth: The company's financial performance in 2024 was notably highlighted by strong revenue growth, particularly driven by the sales of key products such as Mounjaro and Zepbound. For instance, the third quarter (Q3) of 2024 saw a 20% increase in revenue, with a substantial portion of this growth attributed to the volume sales of these drugs, despite a partial offset from the revenue generated in Q3 2023 through the sale of rights for the olanzapine portfolio (Zyprexa).
3. Impressive EPS and Revenue Guidance: The company's earnings per share (EPS) and revenue guidance for 2024 were revised upwards, reflecting confidence in continued growth. The updated guidance for 2024 revenue was set at $45.4 to $46.0 billion, with the EPS guidance ranging from $12.05 to $12.55 on a reported basis, and $13.02 to $13.52 on a non-GAAP basis, both influenced by acquired intangible research and development (IPR&D) charges.
4. Regional Variations in Revenue Growth: There was a notable 42% increase in total revenue in the U.S., driven by a 27% rise in volume and a 15% increase due to higher realized prices. This growth was predominantly led by Mounjaro, Zepbound, and Verzenio, indicating that these products were the primary contributors to the company's revenue and, by extension, its other fees in 2024.
5. Investment in R&D and Marketing: The company's investment in research and development (R&D) and marketing, selling, and administrative expenses increased, reflecting ongoing efforts to support new product launches and innovation, which could indirectly influence other fees related to these activities.

In summary, while specific figures for other fees are not available, the overall financial performance of Eli Lilly in 2024 was robust, with significant revenue growth driven by key products. This growth, in turn, would likely have had a positive impact on other fees, although the exact figures are not detailed.